Clinical Trials Logo

Clinical Trial Summary

The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence threshold among youth and adults and impact of nicotine reduction on tobacco product use behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is necessary for accurately assessing dose-response and threshold effects. The estimated threshold for reinforcement will establish a benchmark for evaluating the addictive potential of ECs and other inhaled nicotine products.


Clinical Trial Description

A placebo-controlled study that will recruit male and female nicotine dependent smokers/EC users (n=18) to complete four separate experimental sessions. Each session will include one randomly assigned infusion that will be either saline or a single dose of nicotine (1 mg per 70 kg body weight) delivered at three different infusion rates, rapid, moderate or slow (0.24, 0.048 or 0.024 mcg per kg body weight per second). A total infusion duration of 10 min will be maintained during each session by adding saline infusions of variable duration after nicotine delivery. This will be achieved by two separate infusion pumps, one for saline and one for nicotine. For example, the rapid 0.24 mcg/kg/s condition will include a 1 min infusion of nicotine followed by a 9 min infusion of saline. The subjects will be blinded to the infusion pump procedures. The rapid delivery rate, which we have used in our prior studies, induces positive subjective drug effects and suppresses symptoms of nicotine withdrawal. The moderate delivery rate,0.048 mcg/kg/s, approximates the rate of nicotine intake encountered while smoking a typical cigarette over 5 min (4). The slowest nicotine delivery rate, 0.024mcg/kg/s, was chosen to approximate the rate of nicotine intake encountered while using a newer EC (5). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03134339
Study type Interventional
Source Yale University
Contact
Status Completed
Phase Early Phase 1
Start date January 5, 2017
Completion date January 29, 2018

See also
  Status Clinical Trial Phase
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Completed NCT04124432 - Behavioral Pharmacology of Cannabis and Nicotine Phase 1
Enrolling by invitation NCT04038515 - Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes Phase 2
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A
Recruiting NCT05864586 - Developing E-liquid Product Standards (Sweet Spot Study) N/A
Completed NCT01227343 - Nicotine and Brain Imaging Research Study
Completed NCT05317195 - Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers N/A
Withdrawn NCT03010995 - The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study Phase 1
Active, not recruiting NCT04189146 - Inner Engineering Yoga Program on Short and Long Term Health Effects (ISHA-Impact): A Longitudinal Study N/A
Completed NCT05487456 - Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence N/A
Completed NCT03102931 - Switching to Low Oxidant Content Cigarettes in Adult Smokers N/A
Recruiting NCT06346353 - Substance Consumption, Personality, and Cognitive Functioning of Chess Players
Completed NCT05383508 - Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes N/A